Search results
Showing 76 to 90 of 123 results for rheumatoid arthritis
risk in patients with causes of secondary osteoporosis other than rheumatoid arthritis and to establish whether their effect on fracture...
group. Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued
accurately. Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued
treatment. Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Osteoarthritis in over 16s: diagnosis and management (NG226)
This guideline covers the diagnosis, assessment and non-surgical management of osteoarthritis. It aims to improve management of osteoarthritis and the quality of life for people with osteoarthritis.
This quality standard covers diagnosing, assessing and managing osteoarthritis in adults aged over 16. It includes treatment and support, and referral for joint surgery. It describes high-quality care in priority areas for improvement.
View quality statements for QS87Show all sections
Sections for QS87
- Quality statements
- Quality statement 1: Diagnosis
- Quality statement 2: Assessment at diagnosis
- Quality statement 3: Information and support
- Quality statement 4: Therapeutic exercise
- Quality statement 5: Weight loss
- Quality statement 6: Follow-up
- Quality statement 7: Core treatments before referral for consideration of joint surgery
Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.
Tofacitinib for treating active ankylosing spondylitis (TA920)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
Tofacitinib for moderately to severely active ulcerative colitis (TA547)
Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults.
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]
In development [GID-TA11244] Expected publication date: TBC
Discontinued [GID-TAG402]